SeraNovo (Leiden, The Netherlands) has closed a multi compound deal with Ildong Pharmceutical (Seoul, South Korea), a pharmaceutical company engaged in the research and development of small molecules in the field of neuroscience and oncology.

SeraNovo is a formulation technology provider enhancing the bioavailability of poorly soluble APIs. The company specializes in addressing two core issues with their proprietary technology: enhancing bioavailability and reducing development time to the clinic.

Niall Hodgins, CEO of SeraNovo, commented: “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with Ildong.”